Artículos por temáticas

Circadian fatigue or unrecognized restless legs syndrome? The post-polio syndrome model.

Romigi A, Maestri M.

Front Neurol. 2014 Jul 7;5:115. doi: 10.3389/fneur.2014.00115. No abstract available.

Restless legs syndrome after high-risk TIA and minor stroke: association with reduced quality of life.

Boulos MI, Wan A, Black SE, Lim AS, Swartz RH, Murray BJ.

Sleep Med. 2017 Sep;37:135-140. doi: 10.1016/j.sleep.2017.05.020. Epub 2017 Jun 30.

Long-term use of pramipexole in the management of restless legs syndrome.

Lipford MC, Silber MH.

Sleep Med. 2012 Dec;13(10):1280-5. doi: 10.1016/j.sleep.2012.08.004.

Restless Legs Syndrome: Psychiatric Comorbidities Are More Important Than Neuroticism.

Trautmann E, Barke A, Frisch JU, Schmidt AL, Kunert F, Canelo M, Sixel-Döring F, Trenkwalder C.

Behav Sleep Med. 2015;13(5):375-86. doi: 10.1080/15402002.2014.919917.

Motor hyperactivity of the iron-deficient rat - an animal model of restless legs syndrome.

Lai YY, Cheng YH, Hsieh KC, Nguyen D, Chew KT, Ramanathan L, Siegel JM.

Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27133. [Epub ahead of print]

Incremental effects of restless legs syndrome on nocturnal blood pressure in hypertensive patients and normotensive individuals.

Erden EC, Erden İ, Türker Y, Sivri N, Dikici S, Ozşahin M.

Blood Press Monit. 2012 Dec;17(6):231-4. doi: 10.1097/MBP.0b013e32835b5a39.

The role of intravenous iron for the treatment of restless legs syndrome.

Auerbach M.

Am J Hematol. 2014 Oct;89(10):1016. doi: 10.1002/ajh.23820. No abstract available.

Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.

Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, Mestre T, Costa J, Trenkwalder C, Ferreira JJ.

Neurology. 2017 May 10. pii: 10.1212/WNL.0000000000004004. doi: 10.1212/WNL.0000000000004004. [Epub ahead of print]

Exome sequencing in a family with restless legs syndrome.

Weissbach A, Siegesmund K, Brüggemann N, Schmidt A, Kasten M, Pichler I, Muhle H, Lohmann E, Lohnau T, Schwinger E, Hagenah J, Stephani U, Pramstaller PP, Klein C, Lohmann K.

Mov Disord. 2012 Nov;27(13):1686-9. doi: 10.1002/mds.25191.

Prevalence of restless legs syndrome and sleep quality in carriers of the fragile X premutation.

Summers SM, Cogswell J, Goodrich JE, Mu Y, Nguyen DV, Brass SD, Hagerman RJ.

Clin Genet. 2014 Aug;86(2):181-4.

Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study.

Takahashi M, Nishida S, Nakamura M, Kobayashi M, Matsui K, Ito E, Usui A, Inoue Y.

PLoS One. 2017 Mar 6;12(3):e0173535. doi: 10.1371/journal.pone.0173535. eCollection 2017 Mar 6.

Contemporary challenges and strategies for improving outcomes for patients with restless legs syndrome.

Buchfuhrer MJ.

Am J Manag Care. 2012 Nov;18(12 Suppl):S283-90.

[Large therapy studies. New options for restless legs syndrome therapy].

Müller T.

MMW Fortschr Med. 2014 Jul 24;156(13):28. German. No abstract available.

New concepts in the management of restless legs syndrome.

Garcia-Borreguero D, Cano-Pumarega I.

BMJ. 2017 Feb 27;356:j104. doi: 10.1136/bmj.j104. Review.

Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome.

Yang Q, Li L, Yang R, Shen GQ, Chen Q, Foldvary-Schaefer N, Ondo WG, Wang QK.

Mov Disord. 2011 Feb 15;26(3):516-9. doi: 10.1002/mds.23459.